InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Larimar Therapeutics, Inc.

LRMR Clue Score29
United States Fiscal year ends December CIK 0001374690
$2.67 -1.11% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $2.67 −77.22% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Revenue0.0Operating income−58.2Net income−57.9Fiscal year 2017Revenue0.0Operating income−53.0Net income−52.0Fiscal year 2018Revenue0.0Operating income−61.1Net income−61.4Fiscal year 2019Revenue0.0Operating income−23.2Net income−23.1Fiscal year 2020Operating income−42.8Net income−42.5EPS, diluted−3.57Fiscal year 2021Operating income−50.5Net income−50.6EPS, diluted−2.95Fiscal year 2022Operating income−36.5Net income−35.4EPS, diluted−1.37Fiscal year 2023Operating income−41.8Net income−36.9EPS, diluted−0.84Fiscal year 2024Operating income−90.9Net income−80.6EPS, diluted−1.32Fiscal year 2025Operating income−172.5Net income−165.7
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 0.0 0.0 0.0 0.0 n/a n/a n/a n/a n/a n/a
Growth
Operating income −58.2 −53.0 −61.1 −23.2 −42.8 −50.5 −36.5 −41.8 −90.9 −172.5
Net income −57.9 −52.0 −61.4 −23.1 −42.5 −50.6 −35.4 −36.9 −80.6 −165.7
Growth
EPS, diluted n/a n/a n/a n/a −3.57 −2.95 −1.37 −0.84 −1.32 n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−52.0Capital expenditure−0.7Free cash flow−52.6Fiscal year 2017Operating cash flow−43.8Capital expenditure−0.1Free cash flow−43.8Fiscal year 2018Operating cash flow−51.5Capital expenditure−0.1Free cash flow−51.6Fiscal year 2019Operating cash flow−22.7Capital expenditure−0.1Free cash flow−22.8Fiscal year 2020Operating cash flow−42.2Capital expenditure−0.1Free cash flow−42.3Fiscal year 2021Operating cash flow−42.1Capital expenditure−0.3Free cash flow−42.4Fiscal year 2022Operating cash flow−27.6Capital expenditure−0.1Free cash flow−27.7Fiscal year 2023Operating cash flow−33.5Capital expenditure−0.2Free cash flow−33.6Fiscal year 2024Operating cash flow−70.8Capital expenditure−0.5Free cash flow−71.3Fiscal year 2025Operating cash flow−113.2Capital expenditure−0.1Free cash flow−113.3
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −52.0 −43.8 −51.5 −22.7 −42.2 −42.1 −27.6 −33.5 −70.8 −113.2
Capital expenditure −0.7 −0.1 −0.1 −0.1 −0.1 −0.3 −0.1 −0.2 −0.5 −0.1
Free cash flow −52.6 −43.8 −51.6 −22.8 −42.3 −42.4 −27.7 −33.6 −71.3 −113.3
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2016Cash32.4Total debt3.2Net cash (debt)29.2Shareholders’ equity121.7Debt to equity0.03Fiscal year 2017Cash40.8Total debt20.0Net cash (debt)20.8Shareholders’ equity78.2Debt to equity0.26Fiscal year 2018Cash49.3Total debt20.0Net cash (debt)29.3Shareholders’ equity2.9Debt to equity6.86Fiscal year 2019Cash1.0Total debt14.5Net cash (debt)−13.5Shareholders’ equity−0.7Fiscal year 2020Cash68.1Shareholders’ equity89.7Fiscal year 2021Cash70.1Shareholders’ equity64.4Fiscal year 2022Cash26.8Shareholders’ equity110.9Fiscal year 2023Cash26.7Shareholders’ equity81.7Fiscal year 2024Cash33.2Shareholders’ equity171.8Fiscal year 2025Cash85.4Shareholders’ equity78.1
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 32.4 40.8 49.3 1.0 68.1 70.1 26.8 26.7 33.2 85.4
Total debt 3.2 20.0 20.0 14.5 n/a n/a n/a n/a n/a n/a
Net cash (debt) 29.2 20.8 29.3 −13.5 n/a n/a n/a n/a n/a n/a
Shareholders’ equity 121.7 78.2 2.9 −0.7 89.7 64.4 110.9 81.7 171.8 78.1
Debt to equity 0.03 0.26 6.86 n/a n/a n/a n/a n/a n/a n/a

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022† 31 Dec 2022 FY2023† 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
0.0 0.0 0.0 0.0 n/a n/a n/a n/a n/a n/a
Growth
39.9 40.8 47.9 20.8 31.4 38.4 24.3 27.7 73.3 154.2
18.3 12.2 13.2 2.4 11.4 12.1 12.3 14.1 17.6 18.3
−58.2 −53.0 −61.1 −23.2 −42.8 −50.5 −36.5 −41.8 −90.9 −172.5
Growth
−57.9 −52.0 −61.4 −23.2 −42.5 −50.6 −35.4 −36.9 −80.6 −165.7
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
−57.9 −52.0 −61.4 −23.1 −42.5 −50.6 −35.4 −36.9 −80.6 −165.7
Growth
Per share
n/a n/a n/a n/a −3.57 −2.95 −1.37 −0.84 −1.32 n/a
n/a n/a n/a n/a −3.57 −2.95 −1.37 −0.84 −1.32 n/a
Growth
n/a n/a n/a n/a 11.9 17.2 25.8 43.9 61.3 n/a
n/a n/a n/a n/a 11.9 17.2 25.8 43.9 61.3 n/a
Growth +44.4% +50.1% +70.4% +39.5%

† The diluted share count jumps at 2022 and 2023, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 10 of 10 years on file.